Introduction {#s0010}
============

Albeit largely neglected by the medical community overall, olfaction is indisputably critical in the manner in which we as humans interact with our environment. Our ability to recognize environmental dangers, such as fires, gas leaks, or ingested toxins, depends heavily on the existence of an intact olfactory pathway such that any disturbance thereof may engender significant safety concerns ([@bb0535]; [@bb0675]; [@bb0080]; [@bb0600]). Olfactory disturbances may also alter our qualitative appreciation of our environment with olfaction being shown to play an influential role in the human emotional response and memory processing ([@bb0125]). It is, therefore, not surprising that individuals afflicted with a disordered sense of smell report significant reductions in quality of life (QOL) as a result of adverse influences on one\'s daily life and mental health ([@bb0180]; [@bb0240]).

As the initial anatomical structure in the olfactory pathway, the nasal airway plays a crucial role in the transmission and perception of olfactory stimuli. Sinonasal pathology, in turn, makes up a critical proportion of etiologies underlying olfactory disturbances. Among patients presenting for clinical evaluation of olfactory impairment, rhinitis and/or rhinosinusitis comprises the most frequent etiology ([@bb0120]). Chronic rhinosinusitis (CRS) is also among the most epidemiologically significant chronic inflammatory disease processes affecting up to an estimated 16% of the American adult population annually and generating approximately \$10 billion per year in U.S. national healthcare costs ([@bb0265]; [@bb0095]; [@bb0735]). In sum, the nasal cavity and its associated diseases represent an essential component in the diagnostic and therapeutic approach of olfactory disturbances. The aim of this chapter is to provide an in-depth review of sinonasal diseases contributing to olfactory dysfunction with particular attention given to the differential diagnosis, physiopathology, clinical approach, treatment strategies, and prognostic factors of sinonasal hyposmia or anosmia.

Nasal Olfactory Anatomy and Physiology {#s0015}
======================================

The nasal contribution to olfaction is closely related to nasal airflow and nasal mucosa integrity. Odorants within inspired air travel through the nasal passageway, traversing the nasal vestibule and nasal cavity to eventually interface with olfactory receptors situated in the olfactory neuroepithelium located on the superior nasal septum, olfactory cleft, and portions of the superior and middle turbinates ([@bb0130]; [@bb0470]; [@bb0625]; [@bb0870]). Along this route, air passes through regions of restricted cross-sectional area such as the internal nasal valve and nasal turbinates that render the airflow turbulent, thereby facilitating odorant delivery to the olfactory epithelium. Approximately 15% of inspired air will be diverted to the olfactory cleft in this fashion ([@bb0260]; [@bb0845]). This sequence of airflow, termed orthonasal olfaction, is what has been traditionally conceptualized as the principle mechanism for mediating olfaction ([@bb0290]). Odorants may also be perceived through retrograde passage of odorants from the oral cavity and oropharynx into the nose via the nasopharynx, termed retronasal olfaction ([@bb0585]). This process is thought to be an important mediator of flavor appreciation and likely contributes to the perception of gustatory loss expressed by patients with a primarily olfactory disturbance ([@bb0255]).

Classification of Olfactory Disturbances {#s0020}
========================================

Olfactory disturbances of sinonasal origin may broadly be classified mechanistically into one of two categories: conductive or neurosensorial. Conductive olfactory loss signifies an underlying airflow etiology. This commonly arises in the setting of sinonasal disease, wherein various pathologies may anatomically obstruct nasal airflow to the olfactory cleft and other mucosal regions lined with olfactory neuroepithelium. The spectrum of pathologies that may give rise to this form of olfactory dysfunction includes CRS particularly among those with nasal polyposis, sinonasal neoplasms, allergic rhinitis, and septal deviations. A neurosensorial olfactory loss signifies damage or dysfunction at any point along the olfactory neural pathway from the olfactory receptors through to the central olfactory processing centers in the brain. The latter category may include local etiologies such as upper respiratory viral illness and toxin inhalation injury to central processes such as neurodegenerative disease, congenital anomalies, and head trauma ([@bb0840]; [@bb0150]). In some instances, both mechanisms of olfactory loss may be contributory as in the case of nasal inflammatory diseases such as CRS ([@bb0380]; [@bb0020]), which will be elaborated upon elsewhere in this chapter.

A descriptive classification of olfactory disturbance is also widely employed to further qualify the nature of the olfactory disturbance. This may take the form of a quantitative classification in which a partial loss is termed hyposmia and a complete loss is referred to as anosmia. Qualitative olfactory disturbances (also known as dysosmia) include parosmia, a distortion in olfactory perception in the presence of an odorant, and phantosmia, a perception of odor in the absence of exposure to an odorant stimulus. The exact pathophysiologic mechanism for qualitative distortions in olfaction has yet to be clearly elucidated though both peripheral and central theories have been proposed corresponding to a dysfunction at either the level of the olfactory neurons or central olfactory processing centers, respectively ([@bb0455]).

Causes of Sinonasal Hyposmia and Anosmia {#s0025}
========================================

Postviral olfactory loss {#s0030}
------------------------

Upper respiratory tract viral infection (URTI) is among the most common etiologies of olfactory loss accounting for up to 43% of cases of neurosensorial olfactory disorders ([@bb0090]; [@bb0180]; [@bb0620]; [@bb0700]; [@bb0795]). Women and people over the age of 65 appear to be more likely afflicted with an olfactory loss following a URTI although the exact reason for this observed predilection remains unclear ([@bb0795]). Some authors have hypothesized a gerontologic predisposition may be due in part to a cumulative damage sustained by the olfactory epithelium ([@bb0135]). Others have suggested a female predilection may result from increased viral exposure possibly due to more frequent contact with children ([@bb0695]). Olfactory loss arising in a postviral setting is more often described as partial (hyposmia) than complete (anosmia) compared to other common etiologies of disturbed olfaction ([@bb0090]; [@bb0180]; [@bb0840]). A postviral olfactory disturbance may also manifest as dysosmia, with patients more often presenting with parosmia compared to phantosmia ([@bb0455]).

The exact viral pathogen responsible for this clinical entity continues to elude researchers, with evidence equally lacking regarding a viral etiology altogether ([@bb0695]; [@bb0840], [@bb0845]). Pathogens identified within the nasal discharge of patients with postviral olfactory dysfunction include rhinovirus, coronavirus, parainfluenza virus, and Epstein--Barr virus ([@bb0785]). Nonetheless, an extensive body of literature has furnished histopathologic evidence of disruption at various levels along the olfactory pathway following a viral insult. Biopsy specimens obtained in patients with olfactory loss have revealed distinct olfactory epithelial changes compared to specimens from normal controls. Changes observed include both a reduction and complete absence of olfactory receptors, replacement of olfactory epithelium by respiratory or metaplastic epithelium, morphologic changes to the olfactory receptors, and disrupted epithelial neural connections ([@bb0850], [@bb0855], [@bb0860]; [@bb0560]; [@bb0340]). Some evidence in this patient population suggests a correlation between the severity of olfactory loss and observed reductions in olfactory receptor density ([@bb0695]), although other researchers have failed to replicate this finding ([@bb0860]). Various animal models have also shown degeneration of the central olfactory pathways including the olfactory bulb following intranasal viral inoculation ([@bb0555]; [@bb0605]; [@bb0690]). These data are further supported by radiologic studies of postviral olfactory loss in humans revealing both anatomical and functional changes to central olfactory structures. Magnetic resonance imaging (MRI) of the olfactory bulb in patients presenting with a postinfectious olfactory loss has revealed significant reductions in olfactory bulb volume that correlate both with the degree and duration of olfactory loss ([@bb0640], [@bb0645]). Moreover, functional brain imaging in these patients employing ^18^fluorodeoxyglucose positron emission tomography (^18^FDG-PET) has demonstrated significant reductions in basal metabolism within specific brain regions responsible for reception and integration of olfactory information ([@bb0395]).

Traditionally, the prognosis of olfactory recovery in postviral olfactory loss has been described as poor, with only one-third of patients demonstrating a recovery in olfactory ability ([@bb0295]). Moreover, the length of dysfunction has been reported to correlate with the likelihood of recovery ([@bb0845]). In the largest and most definitive study on the recovery of olfactory function from any cause (\~ 38% of which were postviral olfactory loss), the strongest positive predictor of olfactory recovery was the degree of initial dysfunction ([@bb0510]). However, long-term follow up of these patients has proved more promising, with improvements in objective olfactory function observed in patients with postviral olfactory loss followed for over 1 year ([@bb0210]). In a recent study of the long-term prognosis of postviral olfactory loss for which subjects were followed for a mean length of over two and a half years, subjective improvement in olfactory ability was reported by over 85% of subjects. Interestingly, an increased length in follow up (\> 2 years) was found to be predictive of improvement in subjective olfactory function. The latter finding would appear to suggest that either the regenerative process of the olfactory pathway continues long after the initial viral insult or that patients merely become accustomed to the olfactory dysfunction over time ([@bb0450]).

Sinonasal surgery {#s0035}
-----------------

A variety of surgical interventions within the sinonasal cavity may inadvertently alter olfactory function. Landis et al. proposed four mechanisms in which surgical interventions of the sinonasal tract may yield an olfactory disturbance: scar tissue, granulation tissue, persistent mucosal edema, and inflammation or damage of the olfactory neuroepithelium ([@bb0435]). Wrobel and Leopold have since modified this scheme to better encompass the spectrum of pathophysiologic processes arising in a perioperative setting. The authors broadly classified mechanisms of olfactory injury following sinonasal surgery into one of four categories: mechanical injury, airflow modifiers, vascular/neural injury, and others. Mechanical injuries allude to direct trauma of the olfactory epithelium (e.g., thermal injury from electrocautery, olfactory fila traction with superior septoplasty and/or osteotomies), scarring, or atrophic rhinitis-related crusting due to overaggressive resection of intranasal structures (e.g., turbinates). Airflow modifiers include any anatomical sequelae (e.g., scarring) that may alter airflow to the olfactory neuroepithelium. Vascular comprise may arise with surgically created ischemia of the olfactory epithelium with neural injury resulting from postoperative URTI. Other mechanisms include topical or locally infiltrated medications in addition to previously unrecognized olfactory disturbances ([@bb0845]). Olfactory loss has also been described in association with general anesthesia, although the exact mechanism of this relationship remains unclear ([@bb0015]).

Despite the manifold means by which olfactory disturbances may arise following sinonasal surgery, the literature would suggest that this complication is rare overall. In a review of over 90 cases encompassing a variety of sinonasal procedures, Kimmelman reported a transient olfactory loss in one-third of patients with a permanent loss occurring in a single patient (1%) ([@bb0425]). These findings parallel those reported by Stevens and Stevens, wherein the vast majority of patients expressed either no change or an improvement in olfactory ability following sinonasal surgery with a single patient manifesting anosmia following a septorhinoplasty ([@bb0780]). Though a postoperative reduction in olfactory ability may infrequently occur following sinonasal surgery, over 10% of patients may report a smell loss preoperatively, prompting a need to document this fact to avoid postoperative accusations of a surgical complication ([@bb0085]).

The risk of permanent olfactory loss appears to be equally infrequent when evaluating specific sinonasal procedures. Given the presence of olfactory epithelium on the superior portion of the middle turbinates, there exists a potential risk of inducing an olfactory loss, following their partial or complete resection. In a cohort of over 100 patients undergoing partial middle turbinate resection during endoscopic sinus surgery (ESS), a single patient endorsed postoperative anosmia accounting for an overall incidence of 0.9% ([@bb0070]). Despite there being no mention of pre and postoperative objective olfactory testing, this reported rate of anosmia compares favorably to that of an ESS cohort wherein the middle turbinates were preserved (0.8%) ([@bb0825]).

Permanent postoperative changes in olfaction following septal surgery likewise manifests in a minority of patients both in so far as olfactory improvement and unanticipated olfactory loss. Pade and Hummel evaluated both pre and postoperative olfactory function in a cohort of 150 patients undergoing septoplasty and noted that the overwhelming majority of patients (81%) endorsed no change in olfaction when assessed at a mean interval of 4 months postoperatively. Improvement in olfaction was related by 13% and only 7% of patients reported decreased function. A separate group of patients who underwent ESS demonstrated a tendency to derive significantly greater olfactory benefit when compared to patients who underwent septoplasty alone. Interestingly, septoplasty patients reporting a loss of smell postoperatively had significantly higher preoperative olfactory scores. These findings suggest that while an olfactory sequela is relatively rare following septal surgery, the potential for this outcome should nonetheless factor into the preoperative counseling of patients undergoing this surgical intervention ([@bb0595]). It is also worthwhile informing patients of the potential for a transient olfactory loss in the acute postoperative setting as a result of mucosal edema and obstructed airflow.

Impairment in olfaction has also been described following rhinoplasty though most of this literature represents lower grades of evidence. In one of the first studies to address this question, Champion published a series of 200 cases whereby subjective evaluation of smell loss was performed for up to 18 months following surgery. A single patient (0.5%) experienced permanent anosmia with 11% of patients reporting temporary olfactory loss ([@bb0105]). Shortly thereafter, Goldwyn and Shore published their series of just under 100 patients for which objective olfactory testing was performed both prior to and following rhinoplasty or submucous resection. The reported incidence of decreased olfactory function was 3% ([@bb0235]).

Skull base surgery {#s0040}
------------------

Anterior skull base approaches for the extirpation of both sinonasal and intracranial pathology carry a significant risk of olfactory complications given the proximity of critical olfactory structures to the surgical field. With the introduction of ESS in the 1980s, minimally invasive endoscopic skull base approaches have increasingly been adopted with the aim of circumventing potential morbidities associated with the traditional open craniofacial approach. While these approaches are conceptually minimally invasive, they frequently require maximal surgical exposure of the endonasal skull base, which entails sacrificing significant portions of peripheral olfactory structures, such as the olfactory epithelium and potentially the olfactory bulb in the case of a transcribriform approach ([@bb0680]). Reconstruction of the skull base defect typically entails harvesting a vascularized, pedicled tissue flap known as a nasoseptal flap, which is largely derived from the mucosa of the nasal septum and may further alter olfactory function.

Although, in theory, endoscopic approaches to the skull base are expected to significantly alter olfactory function, the literature would appear to disagree on the extent of its olfactory impact. Some evidence suggests that contemporary endoscopic approaches may be more favorable insofar as preserving olfactory function compared to the more traditional transseptal microscopic approach that was once widely employed prior to the advent of the endoscope. These two surgical approaches were the subject of a comparative analysis in a prospectively recruited patient cohort undergoing pituitary surgery, wherein olfaction was objectively evaluated preoperatively in addition to 1 and 6 months postoperatively. Patients subjected to a microscopic approach were statistically more likely to sustain an olfactory disturbance compared to the endoscopic group ([@bb0355]). This is not to say that endoscopic pituitary approaches are without olfactory sequela with some groups describing both a subjective and objective decline in olfactory function 6 months postoperatively ([@bb0405]). This observation is not however uniform, with other authors reporting no significant change in objective olfactory function following endoscopic pituitary surgery, irrespective of the employment of nasoseptal flaps ([@bb0100]). Furthermore, statistically significant changes both in three-dimensional volume and cross-sectional nasal passage dimensions observed in patients undergoing an endoscopic transphenoidal approach have not been shown to correlate with a corresponding decline in olfactory function ([@bb0415], [@bb0420]). Yet more extensive endoscopic skull base approaches, commonly termed expanded endonasal approaches (EEAs), do appear to carry a higher risk of engendering an olfactory disturbance. When compared to more limited transphenoidal approaches to the pituitary, EEA patients report significantly greater loss in smell postoperatively though this finding has not replicated with objective olfactory evaluation.

Though olfactory preserving techniques have previously been described for open skull base approaches ([@bb0775]; [@bb0155]; [@bb0300]; [@bb0215]), an increasing awareness regarding potential olfactory sequela following endoscopic skull base surgery has prompted a plethora of literature describing endoscopic techniques for sparing olfactory dysfunction in these patients. These techniques include preservation of the septal olfactory strip ([@bb0245]; [@bb0285]) and use of the cold knife ([@bb0400]; [@bb0310]) (vs electrocautery) during nasoseptal flap harvest in addition to curtailing the routine resection of normal sinonasal structures such as the middle turbinates ([@bb0805]).

Neoplasms {#s0045}
---------

Olfactory dysfunction may occasionally arise in the setting of a sinonasal or intracranial neoplasm. An olfactory deficit in this context may be either conductive or neurosensorial in origin, with the latter resulting from tumoral involvement of the olfactory epithelium and/or olfactory bulbs ([@bb0020]). Intranasal tumors are typically unifocal in nature and more often present with unilateral symptoms more so than bilateral symptoms ([@bb0040]). The most commonly occurring intranasal tumors include squamous cell carcinoma, inverting papilloma, adenomas, and esthesioneuroblastoma ([@bb0020]). The classic example of a nasal tumor giving rise to olfactory dysfunction is an esthesioneuroblastoma, also known as olfactory neuroblastoma (see [Fig. 18.1](#f0010){ref-type="fig"} ). Esthesioneuroblastomas comprise approximately 5% of all sinonasal malignancies and are thought to originate from basal progenitor cells of the olfactory neuroepithelium ([@bb0205]). These tumors often grow insidiously with delays in diagnosis of up to 1 year. They most commonly present with nasal airway obstruction and epistaxis ([@bb0865]), though they often create disturbances in olfaction due to their anatomical origin within the olfactory cleft. Intracranial neoplasms, particularly those located or involving the anterior cranial fossa, may also produce olfactory deficits. Examples of pathologies commonly encountered in this location include olfactory groove meningiomas (see [Fig. 18.2](#f0015){ref-type="fig"} ), frontal lobe gliomas, pituitary adenomas, and craniopharyngiomas ([@bb0050]; [@bb0020]). Neoplasms within the temporal lobe may impair olfaction with up to 25% of such cases presenting as such ([@bb0840]). Tumors in this location are also known to produce olfactory hallucinations ([@bb0485]).Fig. 18.1Esthesioneuroblastoma. Endoscopic (A) and radiologic (B) appearance of an esthesioneuroblastoma. T1-weighted, contrast-enhanced MRI with coronal views (B) demonstrates a hyperintense lesion within the left nasal cavity, contiguous with the olfactory cleft from which this lesion is known to originate. Adjacent sinus opacification is seen within the left maxillary and ethmoid sinuses due to obstruction of the outflow drainage pathway by the tumor.Fig. 18.1Fig. 18.2CT scan of an anterior cranial fossa meningioma. Coronal cut, bone window, noninfused CT scan of the paranasal sinuses demonstrates a soft tissue mass epicentered within the right ethmoid cavity and olfactory cleft with attenuation of the right medial orbital wall indicative of orbital dehiscence. Marked hyperostosis, which is typical of meningiomas involving the skull base, is present.Fig. 18.2

Chronic rhinosinusitis (CRS) {#s0050}
----------------------------

CRS is an epidemiologically important inflammatory condition of the paranasal sinuses with well documented, wide reaching economic implications ([@bb0265]; [@bb0095]; [@bb0735]; [@bb0165]). As per the most recent 2012 European position paper on rhinosinusitis (EPOS), CRS may be defined as the presence of two or more symptoms, one of which must include nasal obstruction or nasal discharge, with or without facial pain/pressure and/or smell disturbance for a period exceeding 12 weeks ([@bb0220]). Clinically, CRS is broadly classified into two subtypes, CRS with nasal polyposis (CRSwNP) and CRS without nasal polyposis (CRSsNP) on the basis of presence or absence of bilateral nasal polyps as identified on nasal endoscopy ([@bb0685]). Despite an exhaustive body of literature dedicated to this disease process, the exact mechanism underlying the pathophysiology of CRS continues to elude researchers in the field. The medical management of CRS, therefore, remains empiric, with a variety of oral and topical therapies proposed directed at combatting both inflammatory and potential microbial contributions to the disease. In the absence of a clinical response, ESS is undertaken with an estimated 450, 000 cases performed annually in the United States alone ([@bb0530]). In addition to restoring mucociliary drainage pathways for the paranasal sinuses, ESS optimizes CRS disease control by optimizing sinonasal mucosal distribution of topical therapies ([@bb0275], [@bb0280]; [@bb0010]; [@bb0740]; [@bb0800]; [@bb0045]; [@bb0830]; [@bb0060]; [@bb0885]).

Impaired olfaction is a frequent complaint among patients afflicted with CRS, with a reported incidence of up to 80% in these patients ([@bb0625]; [@bb0650]; [@bb0345]; [@bb0745]; [@bb0505]). The degree and likelihood of impairment, however, appears to vary based on CRS disease subtype with the most severely and frequently impaired patients comprising those with nasal polyposis (CRSwNP) ([@bb0035]; [@bb0710]; [@bb0820]; [@bb0835]) (see [Figs. 18.3](#f0020){ref-type="fig"} and [18.4](#f0025){ref-type="fig"} ). Employing a regression model, [@bb0025] identified nasal polyposis as the strongest predictor of olfactory impairment in a multicenter cohort of patients with CRS or recurrent acute sinusitis. CRS disease severity, as measured by standardized radiologic and endoscopic scoring systems, was also shown to correlate strongly with the severity of olfactory dysfunction, which concurs with findings reported elsewhere in the literature ([@bb0250]). Soler et al. recently reported a novel endoscopic scoring system entitled the olfactory cleft endoscopic scale that demonstrated high intrarater and interrater reliability in addition to correlating strongly with both self-reported olfaction and objective olfactory evaluation ([@bb0765]). In addition to traditional CT staging systems for CRS, radiologic evaluations of key anatomical sinonasal subsites have also proved valuable in predicting the degree of olfactory burden in CRS patients. Quantitative assessment of olfactory cleft opacification employing three-dimensional computerized volumetric analysis was recently demonstrated to significantly correlate with objective measures of olfaction ([@bb0760]). Additional clinical predictors of olfactory impairment in CRS-identified patients in the literature include comorbid asthma, smoking history, advanced age, recalcitrant disease, and aspirin intolerance ([@bb0495]; [@bb0025]). Histologic and serologic correlates of olfactory impairment in CRS patients include mucosal and serum eosinophilia as well as ethmoid mucosa basement membrane thickening ([@bb0750]; [@bb0325]).Fig. 18.3Normal CT scan of the paranasal sinuses. Coronal cut, bone window, noninfused CT scan of the paranasal sinuses demonstrates normal sinus aeration with absence of sinus mucosal thickening as well as a patent nasal airway and olfactory cleft. Healthy appearing paranasal sinuses are characterized radiologically by an immediate transition from the bone (*white*) of the sinus wall to the air (*black*) of the sinus cavity without any intermediating soft tissue (*gray*) as seen in [Fig. 18.1](#f0010){ref-type="fig"}.Fig. 18.3Fig. 18.4Chronic rhinosinusitis (CR) with nasal polyposis. Radiologic (A) and endoscopic (B) appearance of CR with nasal polyposis (CRSwNP). Coronal cut, bone window, noninfused CT scan of the paranasal sinuses (A) demonstrates complete opacification of the nasal airway, frontoethmoidal recess, ethmoid and maxillary paranasal sinuses consistent with severe CRSwNP. Complete opacification of the olfactory cleft bilaterally is also noted. Endoscopic view (B) of the same patient reveals a significant burden of nasal polyposis extending to the nasal floor and to the anterior most limit of the nasal cavity known as the nasal vestibule, which is lined by hair bearing skin.Fig. 18.4

The pathophysiology of CRS-related smell dysfunction has historically been conceived as being conductive in nature. This concurs with the aforementioned predisposition for olfactory impairment among patients with CRSwNP due to restricted nasal airflow. Clinically, this is best reflected by the transient improvement in nasal airflow and olfaction associated with a reduction in nasal polyp burden frequently observed in these patients following the administration of a high dose corticosteroid taper. In accordance with these observations, several studies have demonstrated the impact of regional nasal anatomy and airflow on olfactory function. Damm et al. demonstrated a significant correlation between olfactory thresholds and the volume of specific intranasal subsites (olfactory cleft and internal nasal valve) as assessed by MRI ([@bb0140]). Employing a computational fluid dynamics (CFD) model to simulate nasal airflow, Zhao et al. demonstrated significant variations in airflow and odorant transport when the same two anatomical regions were altered. While nasal airflow overall did not vary, airflow to the olfactory region and odorant uptake rose dramatically when airway patency at these two subsites were improved ([@bb0875]). Zhao expanded on these findings by demonstrating a significant correlation between olfactory thresholds and odorant absorption within the olfactory region when CFD simulations were applied to a CRS patient cohort ([@bb0880]).

Increasingly, findings have come to light providing evidence in favor of a neurosensorial contribution to the olfactory impairment observed in CRS patients. The earliest evidence in support of this mechanism was a study by Kern in which olfactory mucosa of CRS patients undergoing sinus surgery was histopathologically analyzed for inflammatory changes. The majority of patients manifesting objective olfactory deficits were found to exhibit pathologic inflammatory cellular infiltrate within the olfactory neuroepithelium ([@bb0380]). Further work by Kern et al. provided additional histologic evidence in which increased apoptotic activity was identified within the olfactory neuroepithelium of CRS patients manifesting an olfactory deficit ([@bb0385]). The findings mentioned earlier are confirmed by additional research demonstrating pathologic alterations to olfactory epithelial architecture in CRS patients with olfactory impairment. Histologic findings of olfactory mucosa noted in CRS patients with persistent olfactory loss included epithelial atrophy, squamous metaplasia, reduction in olfactory receptor density, and loss of orderly cell arrangement characteristic of normal olfactory epithelium ([@bb0440]; [@bb0430]). A neurosensorial mechanism of smell loss in CRS for which surgical palliation of the nasal airway following ESS fails to improve olfactory function resonates clinically in those patients. Taken together, the literature to date suggests that a combination of both conductive and neurosensorial mechanisms in CRS likely exists. This may account for the variability in olfactory recovery observed in these patients following medical and surgical management despite objective endoscopic and radiologic improvements in disease burden.

Sinonasal Clinical Evaluation of Olfactory Disturbances {#s0055}
=======================================================

The initial approach to a patient presenting with diminished olfaction demands, above all, a thorough clinical history and physical examination. Patients will often describe altered taste perception but, upon further review, will acknowledge intact taste (sweet, salty, sour, bitter, and umami) with impaired flavor perception. Only rarely will impaired flavor perception represent a true gustatory dysfunction. The vast majority of such complaints will be olfactory in etiology ([@bb0840]) due to the olfactory system\'s contribution to flavor perception through retronasal airflow ([@bb0255]). A detailed history begins with a temporal analysis of the olfactory disturbance, including symptom onset, duration, and evolution. It is essential to quantify the degree of olfactory impairment (hyposmia or anosmia) in addition to probing for any qualitative disturbances in olfactory ability (parosmia or phantosmia).

The three most common etiologies associated with olfactory impairment are head trauma, URTI, and sinonasal disease ([@bb0700]), and a proper history should explicitly elicit the occurrence of such predisposing factors in relation to symptom onset. Contemporary diagnostic criteria for CRS include a history of facial pressure/pain, nasal obstruction/congestion, and purulent/discolored rhinorrhea in association with smell disturbance. Many CRS patients, particularly those with nasal polyps, present with an atopic history, and a review of the patient\'s past medical history should inquire regarding comorbid asthma and allergic rhinitis. Transient olfactory improvement following administration of a high dose corticosteroid taper or topical corticosteroids is commonly seen in patients with CRS. Smell disturbances in this context are typically conductive in nature with olfactory recovery resulting from improved nasal patency following steroid administration.

Neoplastic etiologies (sinonasal or intracranial) may be suspected in the presence of prior epistaxis, unilateral nasal obstruction, or neurologic symptoms such as cranial neuropathies. Foster Kennedy syndrome describes the triad of ipsilateral optic nerve atrophy, contralateral papilledema, and anosmia. It was first described in association with tumors of the anterior cranial fossa causing direct compression of the ipsilateral optic nerve, olfactory bulbs, and intracranial hypertension, resulting in edema of the contralateral optic nerve. It has since been described in association with a variety of other nonneoplastic causes resulting in the same constellation of symptoms and termed pseudo Foster--Kennedy syndrome ([@bb0520]). Patients should also be questioned regarding a personal or familial history of neurodegenerative conditions such as Alzheimer\'s or Parkinson\'s disease. Olfactory dysfunction is a cardinal feature of both of these conditions with up to 90% of patients affected within the early stages of the disease despite most being unaware of this deficit prior to olfactory testing ([@bb0185], [@bb0190], [@bb0195]). Olfactory deficits are also seen in Huntington\'s disease, though such symptoms are primarily reported in patients who already manifest traditional signs of the disease ([@bb0540]). A potential psychiatric history should be explored given the well-established association between olfactory impairment and schizophrenia ([@bb0545]; [@bb0810], [@bb0815]; [@bb0570]; [@bb0670]; [@bb0550]). A history of delayed puberty or infertility may be indicative of idiopathic hypogonadotropic hypogonadism (IHH). The confluence of the latter and anosmia characterizes Kallman\'s syndrome, a rare genetic condition with variable inheritance. Abnormal intrauterine development in these patients results in both an altered hypothalamic--pituitary--gonadal axis and hypoplasia/aplasia of the olfactory bulb/tracts ([@bb0590]). The olfactory deficit in patients with IHH varies along a continuum from complete anosmia (Kallman syndrome) to hyposmia to normosmia, with about one-third of patients displaying each phenotype as reported in a recent study of a large IHH cohort ([@bb0480]).

Additional relevant points to be addressed upon review of the patient\'s past medical history include any oncologic history or prior external beam radiation to the head and neck region. Patients must be questioned regarding past surgical history including prior sinonasal, facial, or neurosurgical interventions. Prior environmental toxin or fume exposure may be elicited upon review of the patient\'s occupational history ([@bb0200]). The patient\'s social history should be assessed for illicit intranasal drug use, topical decongestant abuse, and cigarette smoke, the latter of which is known to adversely affect olfactory function in a dose-related manner ([@bb0225]; [@bb0360]).

Following a comprehensive clinical history, it behooves the consulting physician to perform a complete head and neck examination in the evaluation of a patient of a patient complaining of olfactory dysfunction. Particular importance should be directed toward a thorough endonasal examination in view of identifying a conductive etiology of olfactory loss. This should not merely entail an anterior rhinoscopic examination. The latter has been deemed insufficiently sensitive in discerning conductive pathology with over 50% of such cases missed when a nasal speculum examination was employed in isolation. This figure is reduced to just under 10% when nasal endoscopy is performed in conjunction ([@bb0700]). Elements of the endoscopic examination worth highlighting include a nasal septum deflection, turbinate hypertrophy, mucosal edema, purulent or tenacious secretions, synechia, nasal polyps, and masses. Patency of the olfactory cleft should be evaluated, should the patient\'s anatomy allow for it, with visualization of the air space between the middle turbinate and nasal septum. Assessment of cranial nerve function should also be performed in addition to a fundoscopic examination in view of identifying papilledema. Should the history elicit suspicions of a neurodegenerative condition or dementia, a complete neurologic exam is recommended, including a Mini-Mental Status examination ([@bb0840], [@bb0845]).

Treatment of Quantitative Sinonasal Olfactory Disturbances {#s0060}
==========================================================

Medical therapy {#s0065}
---------------

The vast majority of literature pertaining to the treatment of sinonasal-attributed olfactory impairment has been conducted in patients with CRS. Despite the enigma of CRS pathophysiology, current American ([@bb0655]) and European ([@bb0220]) guidelines support the empiric use of medical therapies in the management of CRS, with surgical intervention reserved for those patients who fail to respond to "maximal medical therapy (MMT)." Though a consensus regarding what exactly MMT entails is notably lacking in the literature, a recent systematic review of MMT protocols prior to ESS identified that the most common therapeutic regimen consisted of an 8-week course of topical intranasal corticosteroids, a 3-week course of broad spectrum or culture directed antibiotics, and a 2-week course of systemic corticosteroids ([@bb0160]).

The administration of corticosteroids in CRS is widely practiced consistent with a consensus in the literature regarding a local inflammatory basis for CRS. Corticosteroids are potent antiinflammatory agents with multiple previously described mechanisms of action including the modulation of inflammatory gene transcription, inflammatory cell infiltration and proinflammatory mediators ([@bb0565]). Corticosteroids are employed both topically and systemically in the management of CRS, with the former preferred as long-term maintenance therapy given its concentration of drug delivery locally with limited systemic absorption and adverse effects. Topically delivered corticosteroids have long been a workhorse in the daily, long-term management of CRS with a plethora of evidence demonstrating its effectiveness in this regard. Topically administered steroids may vary based on mode of delivery, classified as either a standard or nonstandard formulation. A standard delivery topical corticosteroid entails a dose-metered spray that has been approved for nasal use by the Food and Drug Administration ([@bb0665]). This therapy has been assigned the highest level of evidence and grade of recommendation for the management of both CRSwNP and CRSsNP by EPOS 2012 ([@bb0220]) with a recent evidence-based review ([@bb0665]) reiterating these conclusions. Significant improvements in both objective and subjective clinical outcomes of CRS have been consistently demonstrated with this treatment modality. The strength of evidence of systemic (oral) corticosteroids differs considerably, however, based on the presence or absence of nasal polyposis. Recommendations for the use of oral corticosteroids in CRSwNP is founded upon well established, high levels of evidence, whereas a lack of well-controlled studies demonstrating its efficacy in CRSsNP has curtailed support for its use in this patient subset ([@bb0615]).

While the value of the aforementioned therapies have been well established in the overall symptomatic management of CRS, their efficacy in so far as olfactory-specific outcomes is concerned has received comparatively less attention. The most recent and comprehensive review of olfactory outcomes in CRS following medical therapy comprised a systematic review and meta-analysis by [@bb0055]. Unfortunately, only randomized control trials (RCTs) evaluating treatment efficacy in CRSwNP were included in the analysis. A total of 28 RCTs were evaluated with only five trials providing sufficient data for meta-analysis. A meta-analysis of the five studies evaluating oral corticosteroids demonstrated statistically significant improvements in subjective and objective olfactory outcomes compared to placebo. Of note, all of these studies included limited follow up periods (2--8 weeks) consistent with clinical observations concerning the transient olfactory benefit of oral corticosteroids. The evidence in favor of an olfactory benefit following topical steroid administration was comparatively weaker. Insufficient study data precluded data pooling for the purposes of a meta-analysis. A majority of studies (16/22) demonstrated significant improvement in subjective olfactory outcomes following a trial of topical steroids compared to placebo, whereas only a single study (1/8) reported a significant improvement in objective olfactory outcomes. When studies comprising a combination treatment of oral and topical corticosteroids were evaluated, half the studies (3/6) demonstrated a significant subjective olfactory benefit, whereas a single study (1/3) reported a significant improvement in objective olfactory outcomes. Other studies included in this review evaluating alternative medical therapies for CRSwNP received little scientific support for olfactory-specific improvements. These therapies included oral antibiotics (doxycycline and azithromycin), topical antifungals (amphotericin B), herbal therapies, and anti-IgE (omalizumab) ([@bb0055]). A more recent study compared three different modalities of corticosteroid administration (oral corticosteroids, dose-metered budesonide nasal spray, and sonic nebulized budesonide) in CRS for which both disease subsets (CRSwNP and CRSsNP) were equally represented. Interestingly, oral and nebulized corticosteroids yielded equivalent, clinically relevant improvements in objective olfactory measures, which were significantly higher than the standard intranasal formulation. While the latter proved ineffective, the authors noted that the abbreviated duration of therapy (16 days) compared to what is ordinarily employed in clinical practice could have contributed to the absence of effect ([@bb0635]).

Despite representing the most common cause of olfactory dysfunction, there is likewise a limited body of literature demonstrating effective pharmacologic therapies for the treatment of postviral olfactory loss. In a systematic review by Harless and Liang, 8 articles out of a possible 445 abstracts were identified as meeting the study inclusion criteria totaling 563 patients. The various treatments investigated included oral corticosteroids, local corticosteroid injections, zinc sulfate, α lipoic acid, caroverine, vitamin A, Gingko Biloba, and minocycline. The majority of included studies were unfortunately of poor quality with only three studies comprising RCTs. Benefit in objective olfactory outcomes was noted in four of the studied therapies (oral corticosteroid, injected corticosteroid, α lipoic acid, and caroverine), with a single study (caroverine) employing a controlled methodology. Unfortunately, the latter study sample comprised a variety of neurosensorial etiologies with no details regarding the etiologic makeup of each treatment group. It was therefore unclear what benefit patients with postviral olfactory loss specifically derived, given that treatment response was not stratified based on etiology. In all of the studies mentioned so far, the proportion of study patients manifesting objective olfactory improvement represented a minority of the study sample with the highest response rate seen with local corticosteroid injection (49.6%). While promising, the reported frequency and duration of the therapy (every 2 weeks for 8--10 weeks) of locally injected corticosteroids raises serious concerns regarding the clinical feasibility and cost-effectiveness of this treatment modality. Finally, no evidence was identified in support of topical corticosteroids either alone or adjunctive to systemic corticosteroid therapy ([@bb0270]).

Surgical interventions {#s0070}
----------------------

Surgical intervention in the form of ESS is frequently employed as part of the algorithmic approach for the symptomatic management of medically refractory CRS. A wealth of literature has demonstrated that ESS confers significant clinical benefit both in terms of subjective and objective CRS-related outcomes, with a maintenance of these outcomes observed long term ([@bb0715], [@bb0720], [@bb0725], [@bb0730]; [@bb0065]; [@bb0490]; [@bb0315], [@bb0320]; [@bb0790]; [@bb0170]; [@bb0230]). Olfactory-specific outcomes following ESS have proved to be less uniform with disparate findings reporting either a significant, minimal, or absent olfactory benefit ([@bb0345]; [@bb0745]; [@bb0110]; [@bb0115]). The variability in olfactory benefit following surgical intervention for CRS has been attributed to the complex and multifactorial pathophysiology underlying CRS, which is likely both obstructive and neurosensory in etiology ([@bb0660]). This has led to an interesting wave of research bent on further elucidating our understanding of the role of ESS in improving CRS-related olfactory dysfunction through the identification of predictive factors associated with olfactory improvement. While some authors have failed to identify such factors ([@bb0350]), others have demonstrated significant associations between postoperative olfactory outcomes and patient demographics, clinical variables, and preoperative imaging.

In a prospective, multiinstitutional trial comprising over 100 CRS patients who underwent ESS, Litvack et al. identified preoperative olfactory function as a significant predictor of postoperative olfactory improvement. Contrary to their initial hypothesis, patients with severe olfactory dysfunction (anosmia) experienced significant recovery of olfaction, which was sustained at 1-year follow up, whereas patients with milder olfactory dysfunction (hyposmia) did not. Nasal polyposis was also determined to be a significant predictor of improved postoperative olfactory outcome at 12-month follow up. Interestingly, a statistically significant effect modification was noted between preoperative olfactory status and nasal polyposis following a multivariate linear regression analysis. The authors reasoned that the difference in olfactory outcomes observed might have been attributed to complete obstruction of the olfactory cleft in anosmics with nasal polyposis. An obstructive etiology would thereby be amenable to olfactory optimization following surgical extirpation. In contrast, the olfactory impairment in hyposmics without nasal polyposis may have been multifactorial, with ESS less likely to confer improvement in the setting of inflammation-induced neurosensory involvement ([@bb0500]). The value of preoperative olfactory function and/or nasal polyposis as predictors of postoperative olfactory recovery has since been replicated by several other studies ([@bb0595]; [@bb0755]; [@bb0175]; [@bb0410]; [@bb0030]). Moreover, these two variables have also been shown to be independent preoperative predictors of postoperative improvements in QOL outcomes ([@bb0370]).

Despite considerable symptomatic improvements attributed to ESS, a significant proportion of patients will require revision sinus surgery. This appears to be an ongoing area of concern despite the advent of multiple technological advances since the initial inception of ESS. In a recent UK based epidemiologic study of CRS, 20% of CRSwNP patients reported undergoing multiple ESS, with this figure rising to 23% when including patients with allergic fungal rhinosinusitis. The estimated cost burden of repeated surgeries is likewise significant, with a total cost to the U.K. National Health Service likely to be upwards of £30 million annually ([@bb0610]). While both objective and surgical outcomes of CRS appear to improve following revision ESS ([@bb0525]; [@bb0445]; [@bb0705]), the exact impact on olfactory recovery is less well known. A recent prospective study of 32 patients who underwent revision sinus surgery determined the rate of objective olfactory improvement between 12 and 24 months postoperatively to be 48% ([@bb0330]). Other authors have highlighted the prognostic significance of prior surgery in determining the likelihood of olfactory improvement with repeat interventions. The overall consensus among these studies is that prior sinus surgery is a strong predictor of poor olfactory outcomes following subsequent revision sinus surgery ([@bb0145]; [@bb0365]; [@bb0575], [@bb0580]). Furthermore, the likelihood of olfactory function recovery appears to diminish with each subsequent surgical revision with those patients undergoing more procedures experiencing less improvement than those with fewer repeat surgeries. A possible explanation for this finding is surgery-induced injury to the olfactory epithelium with subsequent replacement by nonfunctional respiratory epithelium ([@bb0580]). Coupled with this observation is the influence of the duration of the olfactory deficit and age on olfactory improvement following sinus surgery. Increases in both of these variables have similarly been shown to portend a poor prognosis in so far as olfactory recovery following ESS ([@bb0145]; [@bb0365]; [@bb0575]). This finding is perhaps not surprising given the potential relationship between these three variables: patients subjected to a greater number of surgeries might experience an olfactory deficit for a longer duration of time and may, in turn, be older in age.

Radiologic markers of CRS have also proved informative as it relates to postoperative olfactory recovery. In a prospective study by Soler et al., only baseline CT scores, as graded by a standardized radiologic CRS grading system, were determined to significantly predict postoperative improvement in olfactory-specific QOL ([@bb0770]). Additional studies have provided further insight into the role of preoperative imaging in this regard by evaluating disease severity within various anatomical subsites of the sinonasal cavity. Kim et al. investigated the relationship between the radiologic status of the olfactory cleft and postoperative olfactory outcomes in CRSwNP. The authors determined that preoperative opacification of the anterior olfactory cleft had the strongest negative correlation with postoperative olfactory assessment than any other anatomical region evaluated. This region, the authors reasoned, is a significant determinant of olfactory cleft airflow. Moreover olfactory epithelium appears to be more densely distributed anteriorly than previously assumed. Altogether, disease involvement of this region, given its previously stated role in the olfactory pathway, would appear to significantly influence the potential for olfactory recovery following surgical intervention ([@bb0390]). In a related study, Kim et al. evaluated the relationship between postoperative olfactory performance and radiologic disease severity within various regions of the sinonasal cavity. Individuals demonstrating the greatest olfactory benefit were those with preoperative evidence of partial anterior ethmoid opacification. The authors provided a limited explanation for this finding, speculating only that the olfactory impairment in such individuals may have been more conductive in nature and, therefore, more amenable to surgical intervention ([@bb0410]).

Additional investigations regarding the impact of histologic markers of CRS on olfactory outcomes have been comparatively less fruitful. In a study by Soler et al., a positive correlation was observed between olfactory impairment, basement membrane thickening, and tissue eosinophilia. Yet, once nasal polyposis was controlled, these and other histopathology inflammatory markers failed to predict the likelihood of postoperative olfactory recovery ([@bb0755]). Two other studies that accounted for the histopathology of obstructive lesions within the olfactory cleft (eosinophlic polyps vs respiratory epithelial adenomatoid hamartoma) in CRS patients likewise failed to predict postoperative olfactory outcomes on the basis of this variable ([@bb0575], [@bb0580]).

Treatment of Qualitative Olfactory Disturbances {#s0075}
===============================================

Medical therapy {#s0080}
---------------

Qualitative olfactory disturbance is a poorly understood clinical entity with an elusive pathophysiology for which both central and peripheral theories have been proposed ([@bb0455]; [@bb0305]). Qualitative olfactory impairment often occurs in conjunction with a quantitative olfactory loss, with one series reporting a partial or complete loss in up to 100% of patients manifesting a distortion in smell perception ([@bb0075]). Many patients will report a gradual decrease in symptoms over time, with over 50% of phantosmia patients and close to 30% of parosmic patients experiencing a relief in symptoms within a 12-month observation period according to one series ([@bb0630]). This has led some authors to advocate in favor of a watchful waiting approach as an initial management strategy for patients reporting an olfactory distortion ([@bb0305]). Wherein the olfactory distortion persists, a variety of medical interventions have been proposed, though none of them are supported by particularly high levels of scientific evidence, nor do they convey long-term normalization of olfactory function. The simplest and most economical medical therapy involves the application of nasal saline drops in the head down and forward position (otherwise known as Moffet\'s position), which may be placed at frequent intervals in limitless quantity. While this is not deemed to be effective in all instances, it may provide a short-lived symptom reduction for those patients whose olfactory distortion can be inhibited with nasal occlusion, which is the same effect produced with the application of nasal saline drops ([@bb0455]; [@bb0305]). Oxymetazoline, a topical decongestant in which a rebound mucosal edema (termed rhinitis medicamentosa) ensues when applied long term, may be similarly effective by obstructing nasal airflow ([@bb0455]). An additional conservative strategy involves the withdrawal and/or replacement of medications suspected of being causally related to the olfactory distortion ([@bb0305]).

The employment of α lipoic acid in patients with postviral olfactory dysfunction was the subject of a prospective noncontrolled trial by Hummel et al., for which the incidence of parosmia at the time of study\'s onset approached 50%. The compound is a commonly consumed nutritional supplement that has been employed in the treatment of diabetic neuropathy. The therapy was administered for an average period of 4.5 months and was deemed beneficial, given the reduction in the incidence of parosmia (22%) observed at the conclusion of the treatment period ([@bb0335]). Topical application of cocaine solution, first proposed by [@bb0890], has also been the subject of a recent retrospective case series of six phantosmia patients. As a topical anesthetic, topical cocaine was initially theorized to counter olfactory distortions by temporarily anesthetizing peripheral olfactory neurons. The study set out to confirm Zilstorff\'s initial observation of a 100% cure rate of parosmia following topical cocaine application. Although all patients in the current study reported anosmia with absence of the phantom smell following cocainization, this effect was transient and a majority of patients reported a return in olfactory distortion within 1.5 days. Moreover, when questioned over a year and a half after initial cocainization, all patients reported ongoing phantosmia more than 95% of the time. The majority of patients' symptoms were either unchanged or intensified compared to pretreatment levels. The authors thereby rejected this therapy as a long-term treatment strategy for distorted olfaction ([@bb0460]).

Surgical intervention {#s0085}
---------------------

Medically refractory distortions in olfactory perception may be addressed surgically, with a variety of techniques described with high reported rates of success. Though open neurosurgical approaches have been successfully reported ([@bb0375]; [@bb0515]), the significant risks and morbidity resulting from a craniotomy have ultimately limited their widespread use. With the advent of ESS in the 1980s, minimally invasive, endoscopic approaches to the skull base have increasingly been adopted as standard of practice in view of circumventing potential morbidities associated with traditional external approaches ([@bb0680]). In 1991, Leopold et al. described the first case report of a young, 26-year-old female patient who underwent transnasal endoscopic excision of the olfactory neuroepithelium for a debilitating, medically refractory phantosmia. The procedure was deemed a resounding success, yielding both a resolution in the phantosmia in addition to preserving the patient\'s baseline olfactory function ([@bb0465]). The authors subsequently followed this up with a retrospective case series of eight patients who underwent the procedure. Complete resolution of the phantosmia was achieved in seven of eight patients with an improvement or maintenance of the patients' preoperative olfactory function. The authors stated inclusion criteria for the procedure involved chronic (\> 2 years) unilateral phantosmia, which could be eliminated following application of topical cocaine. The procedure involves stripping the olfactory mucosa along the length of the cribriform plate with severing of the underlying olfactory fila. A free mucoperiosteal graft is then placed overlying the surgical defect to limit the potential for a postoperative cerebrospinal fluid leak. Overall, the procedure offers significant promise for symptomatic management of medically refractory olfactory distortions without comprising underlying olfactory ability ([@bb0475]).

Conclusions and Future Directions {#s0090}
=================================

Olfaction represents a critical chemosensory human function in its ability to alert individuals regarding potential environmental dangers in addition to serving as an important determinant of daily QOL. Though olfactory disturbances have historically not garnered widespread interest within the medical community, the last decade has been witness to an increasing awareness and sensitivity to the considerable handicap engendered by the loss of this sense. This has translated into an increasingly diverse body of scientific literature determined to advance our understanding of the etiologic mechanisms of olfactory injury, prognostic determinants of olfactory recovery, and effective treatment modalities for olfactory disturbances. Increasing healthcare reform in the developed world and the anticipated transition to healthcare payment models that reward quality outcomes will no doubt serve to catalyze further interest in this poorly understood yet clinically significant disease entity.

As one of the cardinal symptoms of CRS, olfactory dysfunction contributes considerably to the extraordinary disease burden afflicting this patient cohort. Unfortunately, it is among the most refractory to contemporary medical and surgical therapies, with limited scientific evidence at present supporting viable therapeutic alternatives. Future research must be directed at furthering our understanding of the pathophysiologic mechanisms of olfactory dysfunction in this clinical context with the hope of promoting therapeutic modalities that either preserve and/or restore olfaction. This will also enhance our ability as clinicians to counsel patients regarding the nature of their disability and better orient their expectations regarding the likelihood of olfactory improvement.
